These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 36935177

  • 1. Clinical and immunological characteristics of PD-1 associated fulminant type 1 diabetes mellitus.
    Qiu J, Luo S, Yin W, Li X, Zhou Z.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Jan 28; 48(1):49-58. PubMed ID: 36935177
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Clinical characteristics of immune checkpoint inhibitor-related type 1 diabetes mellitus].
    Qiu JL, Luo SM, Yin WF, Li X, Zhou ZG.
    Zhonghua Yi Xue Za Zhi; 2023 Jan 07; 103(1):38-41. PubMed ID: 36594136
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Clinical and HLA genotype analysis of immune checkpoint inhibitor-associated diabetes mellitus: a single-center case series from China.
    Liu YC, Liu H, Zhao SL, Chen K, Jin P.
    Front Immunol; 2023 Jan 07; 14():1164120. PubMed ID: 37359544
    [Abstract] [Full Text] [Related]

  • 9. Type 1 diabetes related to immune checkpoint inhibitors.
    Tachibana M, Imagawa A.
    Best Pract Res Clin Endocrinol Metab; 2022 May 07; 36(3):101657. PubMed ID: 35450793
    [Abstract] [Full Text] [Related]

  • 10. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
    Wen L, Zou X, Chen Y, Bai X, Liang T.
    Front Immunol; 2020 May 07; 11():2076. PubMed ID: 32973816
    [Abstract] [Full Text] [Related]

  • 11. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
    Yilmaz M.
    J Oncol Pharm Pract; 2020 Jan 07; 26(1):236-239. PubMed ID: 30955467
    [Abstract] [Full Text] [Related]

  • 12. Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: a retrospective case series.
    Ishi A, Tanaka I, Iwama S, Sakakibara T, Mastui T, Kobayashi T, Hase T, Morise M, Sato M, Arima H, Hashimoto N.
    Endocr J; 2021 May 28; 68(5):613-620. PubMed ID: 33790087
    [Abstract] [Full Text] [Related]

  • 13. PD-1 inhibitor-associated type 1 diabetes: A case report and systematic review.
    Lin C, Li X, Qiu Y, Chen Z, Liu J.
    Front Public Health; 2022 May 28; 10():885001. PubMed ID: 35991054
    [Abstract] [Full Text] [Related]

  • 14. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
    Yaura K, Sakurai K, Niitsuma S, Sato R, Takahashi K, Arihara Z.
    Tohoku J Exp Med; 2021 Aug 28; 254(4):253-256. PubMed ID: 34373422
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes.
    Kotwal A, Haddox C, Block M, Kudva YC.
    BMJ Open Diabetes Res Care; 2019 Aug 28; 7(1):e000591. PubMed ID: 30899528
    [Abstract] [Full Text] [Related]

  • 17. Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes.
    Miyoshi Y, Ogawa O, Oyama Y.
    Tohoku J Exp Med; 2016 Jun 28; 239(2):155-8. PubMed ID: 27297738
    [Abstract] [Full Text] [Related]

  • 18. Acute-onset diabetes mellitus with ketoacidosis in a nivolumab-treated patient with hepatocellular carcinoma.
    Harsch IA, Konturek PC.
    Wiad Lek; 2018 Jun 28; 71(5):945-948. PubMed ID: 30176620
    [Abstract] [Full Text] [Related]

  • 19. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.
    Clotman K, Janssens K, Specenier P, Weets I, De Block CEM.
    J Clin Endocrinol Metab; 2018 Sep 01; 103(9):3144-3154. PubMed ID: 29955867
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.